
    
      This is A multi-center, randomized, double-blind, parallel controlï¼Œcomparative clinical
      trial.

      The primary objective is to evaluate whether the clinical efficacy of QL1209 and pertuzumab
      are similar in patients with early-stage or locally advanced HER2-positive and estrogen
      receptor/progesterone receptor negative breast cancer.

      The secondary objective are to evaluate whether the clinical safety and immunogenicity of
      QL1209 and pertuzumab are similar in patients with early-stage or locally advanced
      HER2-positive and estrogen receptor/progesterone receptor negative breast cancer.
    
  